Vitamin B derivative helps diabetics with mild kidney disease

A vitamin B6 derivative may help slow or prevent the progression of mild kidney disease in patients with diabetes, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The drug may benefit increasing numbers of patients as the prevalence of diabetes rises.

Approximately 40% of all patients who need dialysis or a can blame diabetes for their kidney problems. Because the number of patients with is expected to double by 2030, the prevalence of kidney failure is sure to increase. New therapies that can delay the progression of may help prevent and save lives. Researchers have wondered whether the drug Pyridorin, a derivative of vitamin B6, may be such a candidate. Pyridorin targets several cellular processes that may be relevant to the progression of diabetic kidney disease.

Edmund Lewis, MD (Rush University Medical Center) and his colleagues within the Collaborative Study Group (a large clinical trial group comprised of various kidney care centers) tested the potential of Pyridorin (generic name pyridoxamine dihydrochloride) for treating patients with diabetic kidney disease.

For one year during the double-blind, randomized, placebo-controlled trial, 317 patients received placebo twice a day, Pyridorin at a dose of 150 mg twice a day, or Pyridorin at a dose of 300 mg twice a day.

Overall, the drug did not provide any benefit over placebo for slowing or preventing the progression of diabetic kidney disease; however, Pyridorin did help patients with only mild forms of the disease.

"It appears the drug may be beneficial in a sub-group of patients with only mild kidney disease but does not appear to be beneficial for patients with more advanced kidney disease," said Dr. Lewis. "The results warrant further trials in patients with mild diabetic kidney disease," he added.

More information: The article, entitled "A Randomized Trial of Pyridorin in Type 2 Diabetes," will appear online on Thursday, October 27, 2011, doi:10.1681/ASN.2011030272

add to favorites email to friend print save as pdf

Related Stories

Promising kidney drug fails in large clinical trial

Oct 27, 2011

What was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN) ...

'Silent strokes' linked to kidney failure in diabetics

Jan 28, 2010

In patients with type 2 diabetes, silent cerebral infarction (SCI) -- small areas of brain damage caused by injury to small blood vessels -- signals an increased risk of progressive kidney disease and kidney failure, according ...

Recommended for you

Where Ebola battles are won

7 hours ago

(HealthDay)—Four hospitals that are home to advanced biocontainment facilities have become America's ground zero in the treatment of Ebola patients.

Depression tied to worse lumbar spine surgery outcomes

9 hours ago

(HealthDay)—Depressive symptoms are associated with poorer long-term outcome in patients undergoing surgery for lumbar spinal stenosis (LSS), according to research published in the Oct. 1 issue of The Sp ...

Ebola death toll edging to 4,900 mark: WHO

10 hours ago

The death toll in the world's worst-ever Ebola outbreak has edged closer to 4,900, while almost 10,000 people have now been infected, new figures from the World Health Organization showed Wednesday.

US to track everyone coming from Ebola nations

10 hours ago

U.S. authorities said Wednesday that everyone traveling into the U.S. from Ebola-stricken nations will be monitored for symptoms for 21 days. That includes returning American aid workers, federal health employees ...

User comments